A contemporary review of Clostridioides difficile infections in patients with haematologic diseases

Area of Science:

• Infectious Diseases
• Hematology
• Microbiology

Background:

• Clostridioides difficile infection (CDI) is a major cause of morbidity and mortality, with high incidence in the United States.
• Patients with hematologic diseases face elevated CDI risk due to frequent hospitalizations and treatments.
• Recurrence of CDI remains a significant clinical challenge despite available antimicrobial therapies.

Purpose of the Study:

• To discuss the contributing risk factors for CDI in patients with hematologic diseases.
• To highlight current and emerging strategies for controlling and mitigating CDI.
• To explore novel therapeutic approaches for CDI management.

Main Methods:

• Review of current literature on CDI pathogenesis and risk factors in hematologic patients.
• Analysis of established and experimental treatment modalities for CDI.
• Discussion of emerging therapies including microbiome-modulating agents.

Main Results:

• Identified key risk factors in hematologic diseases: immunosuppression, chemoradiation, antibiotics, PPIs, opioids, and deficiencies in butyrate and antimicrobial peptides.
• Highlighted the importance of antibiotic stewardship and fecal microbiota transplantation in CDI control.
• Explored promising emerging treatments like pre- and probiotics, immunotherapy, and microbiome-sparing agents.

Conclusions:

• Understanding specific risk factors in hematologic patients is crucial for CDI prevention and management.
• Integrated strategies combining infection control, antibiotic stewardship, and novel therapeutics are essential for reducing CDI burden.
• Emerging treatments offer new hope for managing recurrent and refractory CDI, particularly in vulnerable patient populations.